A 68-Year-Old Female with Advanced Renal Cell Carcinoma : Episode 2

Risk Stratification for Patients with Advanced Renal Cell Carcinoma

September 30, 2022

Video

An expert oncologist explains how to calculate a patient’s risk status and provides an overview of front-line treatment options for patients with advanced renal cell carcinoma and discusses which factors are considered when choosing appropriate treatment.

EP: 1.Expert Perspectives on a Case of Advanced Renal Cell Carcinoma

Now Viewing

EP: 2.Risk Stratification for Patients with Advanced Renal Cell Carcinoma

EP: 3.Clinical Implications of the CHECKMATE 9ER Trial

EP: 4.Role of Cabozantinib and Nivolumab in Advanced RCC

EP: 5.CHECKMATE 9ER: Quality of Life Outcomes

EP: 6.Advanced RCC: Future Perspectives

Related Content

Adding Nivolumab to Tivozanib Fails to Improve Outcomes in Metastatic Renal Cell Carcinoma

Megan Hollasch

September 13th 2024

Article

When added to tivozanib, nivolumab did not lead to improved clinical outcomes in metastatic renal cell carcinoma.

Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

Jordyn Sava;Peter Zang, MD

March 1st 2024

Podcast

In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

Listen

Lenvatinib and Pembrolizumab Combo Breaks New Ground in Non–Clear Cell RCC

Morgan Bayer

September 6th 2024

Article

There are remaining gaps in papillary renal cell carcinoma that data from 3 pending trials hope to fill.

Beyond the First-Line: Economides on Advancing Therapies in RCC

Jordyn Sava;Minas P. Economides, MD

February 1st 2024

Podcast

In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

Listen